Eton Pharmaceuticals Inc

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eton Pharmaceuticals reports robust Q4 earnings, eyes accelerated growth

Eton Pharmaceuticals reported strong financial performance in Q4 2022, with a focus on accelerating growth, expanding product portfolio, and doubling sales and royalty revenue in 2023. The strategic transition to an in-house sales force for key products reflects proactive sales strategy control and market expansion efforts. While facing challenges in managing increased R&D expenses, Eton is well-positioned to capitalize on growth opportunities and achieve its long-term goal of commercializing rare disease products.

Eton Pharmaceuticals Reports Record Sales in Q1 2023, Eyes Growth

Eton Pharmaceuticals delivered impressive Q1 results with record sales and revenue growth, driven by successful product launches and strategic marketing initiatives. While facing challenges in managing expenses and legal matters, the company remains optimistic about its growth prospects and product development plans.

Eton Pharmaceuticals excels in Q2, eyes rare disease expansion

Eton Pharmaceuticals demonstrated strong financial performance and strategic growth initiatives in Q2 2023.
While facing regulatory challenges and timeline risks, the company's focus on rare diseases and acquisitions positions it for future growth.
With a solid cash position, successful product launches, and revenue projections, Eton is poised for continued success and value creation.
Navigating challenges and capitalizing on opportunities will be crucial for Eton to sustain its growth trajectory and maximize shareholder value.

Eton Pharmaceuticals excels in Q3, eyes rare disease market growth

Eton Pharmaceuticals demonstrated strong financial performance in Q3 2023, driven by revenue growth and operational efficiency.
While facing challenges in expense management and short-term profitability, the company remains focused on expanding its product portfolio and market presence.
With a solid cash position, strategic acquisitions, and a clear growth strategy, Eton is poised for continued success and revenue expansion in the coming quarters.

Eton Pharmaceuticals excels in Q4, eyes positive net income in 2024

Eton Pharmaceuticals delivered strong financial performance in Q4 2023, with revenue growth, positive cash flow, and a path to positive GAAP net income in 2024. The company's well-capitalized position, promising pipeline, and strategic growth initiatives position it for continued success. However, managing increasing operating expenses and ensuring the accretive nature of future acquisitions are key challenges.

Eton Pharmaceuticals reports robust Q1 revenue growth and strategic expansions

Eton Pharmaceuticals' Q1 performance reflects consistent revenue growth and strategic advancements.
While facing competition and M&A caution, the company is poised for growth with new products.
Opportunities lie in upcoming NDA approvals, product developments, and maintaining financial discipline.
Overall, Eton's prudent financial management and growth strategies position it for future success.

Eton Pharmaceuticals reports record Q3 earnings, eyes transformative acquisition

Eton Pharmaceuticals delivered strong financial performance in Q3 2024, with robust revenue growth, positive net income, and a strategic acquisition on the horizon. While facing challenges in sales force realignment and increased expenses, the company is poised to capitalize on opportunities with Increlex and ET-400.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eton Pharmaceuticals (ETON) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

What Makes Eton Pharmaceuticals (ETON) a Good Fit for 'Trend Investing'

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants David Krempa – Chief Business Officer Sean Brynjelsen – Chief Executive Officer James Gruber – Chief Financial Officer Conference Call Participants Chase Knickerbocker – Craig-Hallum Operator Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in listen-only mode.

Eton Pharmaceuticals, Inc. (ETON) Q3 2024 Earnings Call Transcript

DEER PARK, Ill., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended September 30, 2024.

Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results

DEER PARK, Ill., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report third quarter 2024 financial results on Tuesday, November 12, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

Aligns with Eton's Mission to Develop and Distribute Medicines that Have a Life Changing Impact for Patients with Ultra-rare Conditions

Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen

DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that the Company will participate at the H.C. Wainwright 26th Annual Global Investment Conference in New York City.

Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to the Eaton Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. [Operator Instructions] Please be advised, this call is being recorded at the company's request.

Eton Pharmaceuticals, Inc. (ETON) Q2 2024 Earnings Call Transcript

DEER PARK, Ill., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter ended June 30, 2024.

Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results

DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the Company's New Drug Application (NDA) for ET-400, a proprietary patented formulation of hydrocortisone oral solution, has been accepted by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 28, 2025.

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript May 9, 2024 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Operator Good afternoon, and welcome to the Eton Pharmaceuticals First Quarter 2024 Financial Results Conference Call. At this time all participants are in listen-only mode.

Eton Pharmaceuticals, Inc. Q1 2024 Earnings Call Transcript

•  Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth•  Acquired PKU GOLIKE®, launched Nitisinone, and submitted a new drug application (NDA) for product candidate ET-400•  Management to hold conference call today at 4:30pm ET

Eton Pharmaceuticals Reports First Quarter 2024 Financial Results

DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced today that Sean Brynjelsen, Chief Executive Officer, and James Gruber, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference in New York as follows:

Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference

- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Product has patent protection through 2043 -

Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)

DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2024 financial results on Thursday, May 9, 2024. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announced it has granted an exclusive license to Eton Pharmaceuticals, Inc. (Nasdaq: ETON) (Eton) for the commercialization of GOLIKE ® family of products in the United States. "This transition is fully aligned with Relief's strategy of moving the GOLIKE products into partnership models in the U.S. and Europe.

Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE

DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it has acquired U.S. rights to PKU GOLIKE® from RELIEF THERAPEUTICS Holding SA (“Relief”) (SIX: RLF, OTCQB: RLFTF, RLFTY).

Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria

Eton Pharmaceuticals, Inc. (ETON) Q4 2023 Earnings Call Transcript

Eton Pharmaceuticals, Inc. (ETON) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to earnings of $0.04 per share a year ago.

Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Lags Revenue Estimates

DEER PARK, Ill., March 14, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today reported financial results for the quarter and year ended December 31, 2023.

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results

DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2023 financial results on Thursday, March 14, 2024. Management will host a conference call and live audio webcast to discuss these results at 4:30 p.m. ET (3:30 p.m. CT).

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024

DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that the United States Patent and Trademark Office (“USPTO”) has granted the Company's U.S. Patent Application No. 18/113,458, which covers the Company's ET-400 product candidate's proprietary formulation of oral liquid hydrocortisone. The patent has an expiration in 2043 and is expected to be listed in the FDA's Orange Book upon the product's approval. The Company has additional patent applications related to the product under review with the USPTO.

Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation

-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Current Nitisinone market is estimated to exceed $50 million annually ---- Product is now available exclusively through Optime Care -- DEER PARK, Ill., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to address unmet needs in patients suffering from rare diseases, today announced the commercial availability of Nitisinone Capsules for the treatment of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. Please see important safety information below. Tyrosinemia type 1 is an ultra-rare condition that is estimated to impact fewer than 500 patients in the United States.

Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules

American Public Education

Cellebrite DI Ltd

Legalzoom.com

Playstudios

After a stellar rally in Wall Street this year, investors with limited funds but desire to participate in the market can bet on low-priced top-ranked stocks like Eton Pharmaceuticals (ETON), LegalZoom.com (LZ), PLAYSTUDIOS (MYPS), American Public Education (APEI) and Cellebrite DI (CLBT).

5 Under-$15 Stocks Wall Street Analysts Recommend Buying

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants David Krempa - Chief Business Officer Sean Brynjelsen - Chief Executive Officer James Gruber - Chief Financial Officer Conference Call Participants Raghuram Selvaraju - H.C. Wainwright Operator Good afternoon, and welcome to the Eton Pharmaceuticals Third Quarter 2023 Financial Results Conference Call.

News for Eton Pharmaceuticals Inc Stock (ETON)